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Abstract
Background: Esophageal cancer is the eighth most common cancer globally. Esophageal adenocarcinoma (EA) and esophageal 
squamous-cell carcinoma (ESCC) are the two major types of  esophageal cancer with poor prognosis. The mechanisms of  the 
progression of  normal esophagus to Barrett’s esophagus (BE) and EA are not fully understood. Mitochondria play a central role 
in generating energy, apoptosis and cell proliferation. Mutations of  mitochondrial DNA (mtDNA) have been identified in many 
diseases including cancers. Mutations of  mtDNA were investigated as a part of  carcinogenesis.
Objective: Our objective is to study whether the 5 kb and 7.4 kb mtDNA deletions are important in the progression of  normal 
esophagus to BE and EA.
Method: In this study, the frequency of  the 5 kb and 7.4 kb deletions in mtDNA were studied in specimens ranging from nor-
mal esophageal tissue to BE and EA and also from ESCC. Seventy six paraffin-embedded tissue samples were studied. Four 
couple primers were used. 
Results: Seventy-six tissue samples were analyzed total. The negative control and the positive control PCR product were detect-
ed in all analyzed samples. The fusion PCR products, which represent the presence of  the deletions, were not detected in any 
of  the samples. 
Conclusion: We can say that, these deletions are not associated with progression of  normal esophagus to BE and EA and they 
do not have an important role in detecting esophagitis, BE, EA, and ESSC.
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Introduction
Esophageal cancer is the eighth-most common cancer 
globally with an estimated 16,640 new cases and 14,500 
deaths during the year in the United States1. It is very 
common and aggressive especially for Asian popula-
tions2. Esophagus adenocarcinoma (EA) and esophageal 
squamous-cell carcinoma (ESCC) are the two major types 
of  esophageal cancer. Both of  them have a poor prog-
nosis. Symptoms often include difficulty in swallowing, 
weight loss, pain when swallowing, a hoarse voice, en-
larged lymph nodes around the collar bone, a dry cough, 
and possibly coughing up or vomiting blood3. The most 
common risk factor for EA is chronic gastroesophageal 
reflux disease (GERD)4. GERD also causes esophagitis. 
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Barrett’s esophagus (BE) is one of  the most common 
premalignant lesions. Esophageal squamous epithelium 
damaged by GERD may be replaced by Barrett’s mucosa, 
a condition in which the normal squamous epithelium of  
the esophagus is replaced by a metaplastic, columnar, or 
glandular epithelium that is predisposed to malignancy5,6. 
Patients with Barrett’s esophagus have 30 to 60 times 
greater risk of  developing EA than the general popula-
tion7. The progression of  BE to EA develops through 
established histologic changes: intestinal metaplasia (also 
known as BE) to low grade dysplasia (LGD), high-grade 
dysplasia (HGD) and EA8,9.
Mitochondria are organelles responsible for generating 
energy in eukaryotic cells. Mitochondria have their own 
genome. Each cell contains several hundred to 1000 mi-
tochondria. Each mitochondrion has 2 to 10 copies of  
mitochondrial DNA (mtDNA), which is transmitted 
through the maternal lineage10. DNA of  mitochondria 
is circular, double stranded, closed DNA of  16569 bp 
in size and represents 0.1~1.0% of  the total genomic 
DNA11. It contains 37 genes encoding 13 peptides for 
the oxidative phosphorylation apparatus, 7 for subunits 
of  complex I, 1 for subunit of  complex III, 3 forsubunits 
of  complex IV, and 2 for subunits of  complex V, as well 
as 22 tRNAs and 2 rRNAs12. It has no introns and repli-
cation rate is very high13. Because of  the reactive oxygen 
species, free radicals and lack of  a sophisticated DNA 
repair mechanism it has a very high mutation rate, about 
10 times higher than nuclear DNA14. 
Mitochondria play a central role in apoptosis and cell pro-
liferation15. Mutations of  mtDNA have been associated 
with seizures, ataxia, cortical blindness, dystonia, exercise 
intolerance, ophthalmoplegia, optic atrophy, cataracts, di-
abetes mellitus, short stature, cardiomyopathy and other 
myopathies, sensorineural hearing loss, and kidney failure 
(http://www.mitomap.org/). There is also an association 
between mtDNA and tumors16-18. Many of  the mtD-
NA mutations associated with cancers occur within the 
non-coding control region (also known as the D-loop) 
of  the mitochondrial genome, which is about 1.1 kb (be-
tween bases 16024 and 576) in size19-22. The D-loop was 
reported to be more susceptible to oxidative damage and 
sequence variation23.
Common 5 kb or 4977-bp deletion is one of  the best-
known mutation in mtDNA, between nucleotides 8,470 
and 13,447. It is associated with many disorders like my-
opathies, Alzheimer disease, cancers, aging and used as 
an indication of  mtDNA oxidative damage2,12,24-26. This 
mutation removes all or part of  the genes encoding four 
complex I subunits, one complex IV subunit, two com-
plex V subunits and five tRNA genes, therefore causing 
energy production catastrophe and abnormal reactive ox-
ygen species generation27. The 7.4 kb deletion is flanked 
by direct repeats and it is between the D-loop and the 
ATPase 6 genes of  mtDNA28. It is associated with ageing 
and cardiac problems28.
In this study the frequency of  the 4977 bp and 7400 bp 
deletions in mtDNA were studied in specimens ranging 
from normal esophageal tissue to BE and EA and from 
ESCC. Our objective is to study whether the 5 kb and 7.4 
kb mtDNA deletions are important in the progression of  




The study was approved by the Ethics Committee of  
Ataturk University. We used 76 paraffin-embedded tis-
sue samples which were histopathologically confirmed. 
The tissues were belonging to the patients living in Tur-
key. Among 33 samples from females, there were 5 nor-
mal esophagus, 8 esophagitis, 8 BE, 7 EA and 5 ESCC; 
and among 43 samples from males there were 5 normal 
esophagus, 6 esophagitis, 8 BE, 17 EA and 7 ESCC. Five 
micron thick sections were taken from each patient's tu-
mor in paraffin-embedded tissue blocks. 
Mitochondrial DNA extraction
Mitochondrial DNA was extracted from formalin fixed, 
paraffin-embedded tissue sections using the QIAamp 
DNA Mini Kit (QIAGEN GmbH, Hilden, Germa-
ny) according to the manufacturers’ instructions. Paraf-
fin was removed by extraction with xylene and ethanol 
(96–100%) added to remove residual xylene. Tissue sam-
ples were washed with phosphate-buffered saline (PBS) 
to remove formalin-fixative. Proteinase K was used until 
the tissue was completely lysed and DNA was extracted. 
DNA concentration and quality was quantified by ab-
sorbance readings taken at 260 and 280 nm using Mae-
stroNano Spectrophotometer (Maestrogen Inc., Hsinchu 
City, Taiwan).
Polymerase Chain Reactions and gel electrophoresis
A duplex polymerase chain reaction (PCR) method was 
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used for amplifications of  target sequences of  mtDNA2. 
Four couple primers were used: the first (L.9590-H.10368) 
was to amplify the negative control sequence within the 
deleted sequence, the second (L.6251-H.7261) was to 
amplify the positive control sequence out of  the deleted 
sequence, the third (L.7901-H.13631) was to amplify the 
4977 bp deletion region and the fourth (L.8531-H.381) 
was to amplify the 7400 bp deletion region (Table 1). 
PCR was performed in Sensoquest Labcycler (Senso-
quest GmbH, Hannah, Germany). Thermal cycle condi-
tions were as follows: an initial denaturation step of  95°C 
for 15 min; 32 cycles of  94°C for 60 s, 55°C for 60 s, 
72°C for 80 s and a final extension step of  72°C for 15 
min. PCR products were resolved together with a marker 
DNA (DNA 100 bp Ladder) on a 2% agarose gel, stained 
with ethidium bromide and visualized under UV transil-
luminator (Figure 1).
Table 1. The primer sequences and the expected sizes of PCR products of the two 
fragments in the control regions and two fragments for deletion regions. 
 
Primers PCR Product 
Sizes 



















L(6251) 5’-TAT AGT GGA GGC CGG AGC AG-3’ 







L(7901) 5’-TGA ACC TAC GAG TAC ACC GA-3’ 







L(8531) 5’-ACG AAA ATC TGT TCG CTT CA-3’ 






Figure 1. The PCR products of esophageal tissues of six patients on 2% agarose gel. “a” represents a 
1019 bp PCR product occurring in case of 7400 bp deletion of mtDNA; “b” represents a 753 bp PCR 
product occurring in case of 4977 bp deletion of mtDNA; “c” represents a 1010 bp PCR product, negative 
control within deletion region; “d” represents a 778 bp PCR product, positive control out of deletion 
region; M represented a marker DNA to detect the size of fragments. 
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Results
In total, seventy-six tissue samples were analyzed. The 
negative control PCR product of  778 bp and the positive 
control PCR product of  1010 bp were detected in all ana-
lyzed samples. The fusion PCR products of  753 bp which 
appears if  there is the 4977 bp deletion of  mtDNA and 
1019 bp which appears if  there is the 7400 bp deletion of  
mtDNA, were not seen in any of  the samples. Due to the 
absence of  the deletions in any sample, statistical analysis 
was not performed.
Discussion
Esophageal cancer, the eighth-most common cancer, 
is aggressive and it has a poor prognosis. GERD caus-
es esophagitis and BE. BE is one of  the most common 
premalignant lesions for EA development7. After the 
process of  carcinogenesis, which is controlled by genet-
ic, epigenetic and environmental factors, the cells gain 
uncontrollable growth capacity29. Mutations of  mtDNA 
were investigated as a part of  this process30-32. Therefore 
it is important to search for mtDNA alterations in pro-
gression of  normal esophagus to BE and EA and also for 
other esophageal malignancies.
The mtDNA4977 deletion is associated with ageing and 
in many cancers. The mtDNA4977 deletion was less fre-
quent in cancers when compared with the normal tissues; 
it could be an adaptation mechanism for tumors33-37. Tan 
et al.38 reported that mtDNA4977 deletion could be used 
as a biomarker for dysplasia but not for EA38. Abnet et 
al.2 reported high frequency of  mtDNA4977 deletion in 
esophageal cancer patients from China, but mutation anal-
ysis of  the whole mitochondrial genome from Northern 
India did not find this deletion2,17. This maybe because of  
Chinese population has a high risk for this cancer and it 
is possible that the pathogenesis of  esophageal cancers in 
this population includes mtDNA mutations.
The 7.4 kb mtDNA deletion has been studied in many 
diseases, but only found meaningful in ageing and cardiac 
problems28,39. However the role of  the 7.4 kb mtDNA 
deletion in the progression of  normal esophagus to BE, 
EA and in ESCC is not clear. 
In our study the common deletion was considered pres-
ent if  the primers produced a 753 bp fusion product and 
the 7.4 kb deletion was considered present if  the primers 
produced a 1019 bp fusion product. We used negative 
control within the deleted sequence, because the common 
mtDNA region is very susceptible to oxidative damage 
and deletion of  this part could have different hotspots 
for breakage, and if  there is a deletion in this region we 
would have detected it. However, we could not detect any 
deletions in these regions and controls. 
Conclusion
Our data provides insights for genotype–phenotype cor-
relations of  mtDNA mutations with esophageal diseases. 
Unlike Abnet et al.2, we could say that, the 5 kb and 7.4 
kb mtDNA deletions are not associated with progression 
of  normal esophagus to BE and EA and they do not have 
an important role in detecting and prognosis of  esopha-
gitis, BE, EA, and ESSC. Further studies, especially sin-
gle nucleotide variations and copy number alterations of  
mtDNA, should be undertaken to investigate the effects 
of  mutations on disease in relation with modifiers. 
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